Ensuring quality in cervical screening programmes based on molecular human papillomavirus testing
- PMID: 30657615
- DOI: 10.1111/cyt.12679
Ensuring quality in cervical screening programmes based on molecular human papillomavirus testing
Abstract
The increased use of human papillomavirus testing within cervical screening programmes necessarily brings about changes to the laboratory services required to support them. A crucial element of such services is to demonstrate initial and ongoing quality of the test (and associated processes). In this review, we outline some of the quality considerations and challenges with an emphasis on the laboratory including assay and platform validation, internal quality control selection and strengths and weaknesses of external quality assurance schemes. The influence and role of key external entities, including regulatory agencies, guideline groups, programme commissioners and commercial providers, are also discussed.
Keywords: human papillomavirus; molecular testing; quality assurance; quality control; verification.
© 2019 John Wiley & Sons Ltd.
Similar articles
-
Quality assurance in human papillomavirus testing for primary cervical screening.Int J Gynecol Cancer. 2023 May 1;33(5):802-811. doi: 10.1136/ijgc-2022-004197. Int J Gynecol Cancer. 2023. PMID: 36914171 Free PMC article. Review.
-
The BAC recommended code of practice for cytology laboratories participating in the UK cervical screening programmes 2015 - an introduction.Cytopathology. 2016 Feb;27(1):5-7. doi: 10.1111/cyt.12314. Cytopathology. 2016. PMID: 26818037 No abstract available.
-
HPV testing in cervical cytology practice: it's all about choice.Acta Cytol. 2005 Mar-Apr;49(2):117-9. doi: 10.1159/000326117. Acta Cytol. 2005. PMID: 15839612 No abstract available.
-
Cervical cancer screening and subsequent procedures in women under the age of 25 years between 2007 and 2013 in France: a nationwide French healthcare database study.Eur J Cancer Prev. 2018 Sep;27(5):479-485. doi: 10.1097/CEJ.0000000000000360. Eur J Cancer Prev. 2018. PMID: 28368950
-
[How technology and vaccination have changed the Pap test].Pathologica. 1999 Feb;91(1):36-41. Pathologica. 1999. PMID: 10396949 Review. Italian. No abstract available.
Cited by
-
Integrating human papillomavirus testing as a point-of care service using GeneXpert platforms: Findings and lessons from a Kenyan pilot study (2019-2020).PLoS One. 2023 May 25;18(5):e0286202. doi: 10.1371/journal.pone.0286202. eCollection 2023. PLoS One. 2023. PMID: 37228154 Free PMC article.
-
Cervical cancer programme, Kenya, 2011-2020: lessons to guide elimination as a public health problem.Ecancermedicalscience. 2022 Aug 26;16:1442. doi: 10.3332/ecancer.2022.1442. eCollection 2022. Ecancermedicalscience. 2022. PMID: 36200015 Free PMC article.
-
Clinical implementation of a cervical cancer screening program via co-testing at a university hospital.PLoS One. 2022 Dec 1;17(12):e0278476. doi: 10.1371/journal.pone.0278476. eCollection 2022. PLoS One. 2022. PMID: 36454784 Free PMC article.
-
Quality assurance in human papillomavirus testing for primary cervical screening.Int J Gynecol Cancer. 2023 May 1;33(5):802-811. doi: 10.1136/ijgc-2022-004197. Int J Gynecol Cancer. 2023. PMID: 36914171 Free PMC article. Review.
-
Human Papillomavirus Detection by Whole-Genome Next-Generation Sequencing: Importance of Validation and Quality Assurance Procedures.Viruses. 2021 Jul 8;13(7):1323. doi: 10.3390/v13071323. Viruses. 2021. PMID: 34372528 Free PMC article.